

David Simmons FRACP FRCP MD
Professor of Medicine, Western
Sydney University

Director Endocrinology, Campbelltown
Hospital

Immediate Past President
Australasian Diabetes in Pregnancy Society

Chief Medical Officer
Diabetes Australia

Should we diagnose and
treat early GDM?

SFOG 5th September 2024

Presenter Disclosure

Speaker's Bureau-Ascensia, Abbott, Novo-Nordisk

Consultant-Sanofi

Educational grant- Boehringer Ingelheim, Ascensia

Equipment-Roche

NB-None related to this presentation

Should we diagnose and treat early GDM?

- Where I'm from!
- The 24-28 weeks centric view
- GDM as part of a lifecourse condition
- Evidence for early (<20 weeks') GDM
- Evidence for treating GDM
- Conclusion!



Where is Campbelltown?



NSW's most multicultural city is in Sydney's southwest

IT'S official: Census figures have uncovered NSW's most multicultural city.

Eliza Barr


less than 2 min read July 4, 2017 - 3:08PM Fairfield Advance

0 comments



Gestational diabetes


Global prevalence: **14%** (standardized to IADPSG criteria)



IDF Atlas

References:

International Diabetes Federation. IDF Diabetes Atlas, 10th edn. Brussels, Belgium: International Diabetes Federation, 2021.




OBOGM Study



Reprinted from DIABETES, VOL. 29, NO. 12, DECEMBER 1980
Copyright 1980 by THE JOURNAL OF THE AMERICAN DIABETES ASSOCIATION.

Banting Lecture 1980 Of Pregnancy and Progeny


Potential long-range effects upon the fetus of altered interactions in maternal fuels during pregnancy. Fuel-mediated teratogenesis as the basis for long-range anatomic and functional changes.




Freinkel 1980

Maternal glucose - perinatal outcomes

A Birth Weight >90th Percentile




B Primary Cesarean Section




—◆— Fasting glucose
—■— 1-Hr glucose
—▲— 2-Hr glucose

C Clinical Neonatal Hypoglycemia



D Cord-Blood Serum C Peptide >90th Percentile



Big study
23316 births
Not an RCT
From 24+/40

24+/40 RCTs

ACHOIS
Landon
GEMS
CDC4G
->Benefit



References:

N Engl J Med. 2008 May 8;358(19):1991-2002.

O Sullivan and Mahan From 1964




Cohort of 752 women in 2nd-3rd trimester

- 100g OGTT-3 hours
- 2+/-4 tests to avoid reliance on one time point
- Thresholds decided
 - using life tables for mother to develop T2DM in 7-8 years
 - Related to diabetes prevalence (2% at the time)

Figure 35.2

Cumulative Incidence of Diabetes in Women with Normal Glucose Tolerance or Gestational Diabetes During Their Index Pregnancy




United States Public Health Service criteria were used to diagnose diabetes during the followup.

Source: Reference 81




Prevalence IGT

2021 2045




Prevalence IFG (6.1+mM)


Prevalence



Many thanks to
Dianna J Magliano
Liz Selvin and the IDF
Atlas IGT/IFG Team

Percent Time >120 mg/dL by Gestational Week and GDM Status






OBOGM Study



Reprinted from DIABETES, VOL. 29, NO. 12, DECEMBER 1980
Copyright 1980 by THE JOURNAL OF THE AMERICAN DIABETES ASSOCIATION.

Banting Lecture 1980 Of Pregnancy and Progeny

Potential long-range effects upon the fetus of altered interactions in maternal fuels during pregnancy. Fuel-mediated teratogenesis as the basis for long-range anatomic and functional changes.





What is
actually
happening:

Freinkel 1980



Maternal Metabolic Characteristics



○ Women with early GDM:

- Higher first and second phase insulin response
- Higher Waist, BP, triglycerides and free fatty acids

Prevalent (Early) GDM: Comparison of pregnancy outcomes with late onset GDM women




Outcome Measure	No of studies (participants)	RR (95% CI) Random effect
Large for gestational age	7(9622)	1.07 (0.86 to 1.35)
Perinatal mortality	7 (9130)	3.58 (1.91 to 6.71)
Neonatal hypoglycemia	7(6818)	1.61 (1.02 to 2.55)
Neonatal intensive care unit admission	5(7992)	1.16 (0.90 to 1.49)
Insulin use	11(8103)	1.71 (1.45 to 2.03)
Small for gestational age	5(5900)	1.27 (0.92 to 1.75)
Hypertensive disorders in pregnancy	10(10091)	1.34(0.98 to 1.82)
Preterm delivery	7(7039)	1.16 (0.84 to 1.61)
Cesarean delivery	9(9685)	1.09(0.94 to 1.26)
Shoulder dystocia	2(2936)	1.76(0.96 to 3.24)

30-70%

All treated, so this is after treatment

Different OGTT criteria (but all used OGTT)

The relationship between maternal first trimester glucose and frequency of adverse pregnancy outcomes




GA 9.5 weeks
n=6,129

Fasting glucose categories:

1. < 4.2 mmol/L
2. 4.2-4.4 mmol/L
3. 4.4-4.7 mmol/L
4. 4.7-4.9 mmol/L
5. 4.9-5.2 mmol/L
6. 5.2-5.5 mmol/L
7. 5.5-5.8 mmol/L

Riskin-Mashiah et al. Diabetes Care 2010

Stratified analysis of the association between GDM and abdominal circumference (AC) >90th percentile at 28 wkGA: **28/40 too late**



But will treatment improve outcomes?

Treatment Of BOoking Gestational diabetes Mellitus Study

TOBOGM Hypothesis

Treatment of 'booking GDM'

- Reduces the sequelae of maternal 'hyperglycaemia'



Main Trial ACTRN12616000924459



The NEW ENGLAND
JOURNAL of MEDICINE

N Engl J Med 2023; 388:2132-2144 DOI:
10.1056/NEJMoa2214956

ORIGINAL ARTICLE

Treatment of Gestational Diabetes Mellitus Diagnosed Early in Pregnancy

D. Simmons, J. Immanuel, W.M. Hague, H. Teede, C.J. Nolan, M.J. Peek,
J.R. Flack, M. McLean, V. Wong, E. Hibbert, A. Kautzky-Willer, J. Harreiter,
H. Backman, E. Gianatti, A. Sweeting, V. Mohan, J. Enticott, and N.W. Cheung,
for the TOBOGM Research Group*

This well-conducted trial provides much needed information regarding the benefits and harms of screening for and treating gestational diabetes in early pregnancy.

N Engl J Med 2023; 388:2132-2144
DOI: 10.1056/NEJMoa2214956

International (India, Sweden, Austria, Australia)
Multicentre single blinded RCT of treating early GDM from “booking” or from OGTT
results at 24-28 weeks’ gestation

TOBOGM Sites



TOBOGM Study

17th May 2017 through 31st March 2022, Last birth October 10th 2022 n=802 in RCT

Participants

Included

- Multicentre study-17 sites-Oz, Swe, India, Austria
- Women aged ≥ 18 years, Singleton pregnancy
- Risk factor for hyperglycemia in pregnancy
- OGTT between 4 and 19⁺⁶ weeks' gestation

Excluded from the RCT:

- Women with pre-existing diabetes, No GDM
- FBG 6.1+mM/2HBG 11.1+mM
- Major active medical disorders



TOBOGM Study Design

Screened
(n =43,721)



OGTTs performed before 20 weeks n=3672



DIP, FBG \geq 110
mg/dl
Excluded
From RCT



Early GDM Randomised into trial n=802



GDM Treatment
Rx Booking
GDM
(Intervention)
n=406



No Treatment
No Rx Booking
GDM (Controls)
n=396

Clinical team
and patient
notified of GDM
diagnosis, early
RX commenced

Clinical team and patient notified
that GDM Rx is not required but
that they have been selected to
continue in the study

24-28/40 Rx:
Birth outcomes
Birth measures

Rx if 24-28/40 GDM on OGTT
Birth outcomes
Birth measures (includes heelprick)



TOBOGM Study

Results-Baseline data

Variables	Booking GDM-Intervention (N=400)		Booking GDM-Control (N=393)	
	n/N	%/	n/N	%/
Age (years)	400	32.1 ±4.8	393	32.6 ± 4.9
Ethnicity				
White European	150/399	37.6	166/391	42.5
South Asian	129/399	32.3	106/391	27.1
East Asian/SE Asian	51/399	12.8	60/391	15.3
Middle Eastern	32/399	8.0	17/391	4.3
Māori and Pacific	24/399	6.0	22/391	5.6
Islands Other (Aboriginal/ African/South American)	13/399	3.3	20/391	5.1



Results

Variables	Booking GDM-Intervention (N=400)		Booking GDM-Control (N=393)	
	n/N	%/	n/N	%/
BMI at first visit (kg/m ²)	399	32.1 ± 7.7	390	32.9 ± 8.4
OGTT < 14+0 weeks' gestation	104/400	26.0%	80/393	20.4%
HbA1c at 1 st OGTT (%) (mmol/mol)	388	5.2 ± 0.3 (33.4 ± 3.7)	384	5.2 ± 0.3 (33.3 ± 3.4)



PO1: composite of

- Birth <37⁺⁰ weeks' gestation
- Birthweight ≥4500g
- Birth trauma (IADPSG criteria)
- Neonatal respiratory distress
- Need for phototherapy
- Stillbirth/neonatal death
- Shoulder dystocia

Higher=O.R 2.0
=5.3/10.6/9.0 mmol/L


Lower =O.R 1.75 not 2.0
Fasting BG 5.1–5.2mM
1-Hr glucose 10.0–10.5mM
2-Hr glucose 8.5–8.9 mM

TOBOGM Results

GTT performed before 20 weeks and at 24-28 weeks



OBOGM Study



Vs 24-28 weeks gestation Treatment RCTs

GDM at 24+/40	Definition	Treated	Control
MFMUN	Not defined	1.9%	2.9%
ACHOIS	Need for supplemental oxygen in the neonatal nursery beyond four hours after birth	5%	4%
GEMS	Use of respiratory support	5.1%	5.6%
CDC4G	ICD-Respiratory distress (at least 4 hours' respiratory support with supplemental oxygen, continuous positive airway pressure, and/or intermittent positive pressure ventilation in the first 24 h after delivery)	0.83%	0.65%
CLS 02-08	Respiratory distress syndrome [RDS], Transient Tachypnea of newborn [TTN] (not defined)	RDS 4.0%+TTN 5.1%=9.1%	
<u>TOBOGM</u>	warranting ≥ 4 hrs of respiratory support with supplemental O ₂	9.8%	17.0%
More severe	Neonatal respiratory distress as above+ Stay in NICU>24 hours	6.3%	9.9%
RDS	Respiratory Distress with admission to neonatal intensive care unit for ≥ 24 hours with positive pressure ventilatory support for >4 hours.	1.8%	2.0%

GDM Treatment	Intervention (n=400)	Control (n=393)
No Neonatal Respiratory distress	52.3% N=363	47.7% N=331
Neonatal Respiratory distress-No or ≤ 1 day in NICU/SCN	34.3% N=12	65.7% N=23
Neonatal Respiratory distress >1 day in NICU/SCN	39.1% N=25	60.9% N=39

P=0.019



OBOGM Study

NICU Bed days

Adjusted Treatment effect
Mean (95% CI)
-0.78 Bed Days (-1.27 to -0.30)

NICU Bed days/Baby

Adjusted Treatment effect
%RR (95% CI)
0.60 (0.41 to 0.89)

Total NICU Bed days

No Difference

- Neonatal hypoglycaemia
- LGA
- Lean mass
- PO2: hypertension in pregnancy- composite of:
 - Preeclampsia
 - Eclampsia
 - Gestational hypertension

Neonatal anthropometry

Variables	Adjusted Treatment effect
	Mean (95% CI)
Birthweight (g)	-72 (-128 to -17)
Sum of neonatal callipers (mm)	-1.4 (-2.2 to -0.5)

Perineal Injury

Adjusted treatment
effect as difference in %
(95% CI)


-2.79
(-4.12 to -1.46)

Adjusted
treatment effect
(95% CI)
RR

0.23
(0.10 to 0.51)

(IADPSG: 3rd or 4th degree tear)

SGA



Lower
band

Adjusted
treatment effect
(95% CI)
RR

1.32
(0.93 to 1.85)

1.75
(1.05 to 2.92)



Increase (sig)

Early OGTT
SBGM, Meds
Endo, CDE, dietitian
OBGYN, ED


Decrease (non-sig)

Delivery
NICU/SCN




OBOGM Study

Cost-effectiveness within the RCT



Cost-effectiveness plane within the RCT



Breastfeeding is improved to background with early treatment vs late

- Adjusted for all confounders including birth/neonatal
- No GDM 1
- Treated early GDM 0.96(0.66-1.38)
- Treated as late GDM 0.62(0.47-0.83)



Some outcomes can not be reversed with late treatment

Mean (95%CI shown)	GDM on early and late OGTT and Rx late	GDM only on late OGTT and Rx'd	No Late GDM
Composite outcome	1.59(1.18-2.12)	1.19(0.94-1.50)	1

No difference in LGA, Ht in pregnancy, LSCS, phototherapy

Adjusting for prespecified factors of site,
age, pre-pregnancy BMI, ethnicity, current smoking, primigravidity, tertiary qualifications;

Simmons D et al, Diabetes Care. 2024 Feb 29;dc231667. doi: 10.2337/dc23-1667. Epub ahead of print. PMID: 38421672.

Summary-Early OGTT and Treatment if GDM

- ↓ 25% Composite (From 10-13+6/40)
 - Birth <37⁺⁰/40; Birthweight ≥4500g; Shoulder dystocia;
 - Birth trauma; Neonatal respiratory distress ; Need for phototherapy; death
- ↓77% Perineal Injury (3rd/4th Deg' tears)
- ↓0.8 bed days NICU/SCN
- ↑73% SGA with lower glucose band
- ↑Quality of Life at 24-28/40
- ↑56% Breastfeeding initiation
- A\$5548 saved per woman tested if before 14/40

Conclusion

- Treatment of gestational diabetes among women with risk factors before 20 weeks' gestation was effective especially 10-14 weeks' gestation and at
 - Fasting glucose 5.3–6.0 mmol/L
 - 1-hour glucose ≥ 10.6 mmol/L
 - 2-hour glucose 9.0–11.0 mmol/L
- Harm was suggested in the lower band (5.1mM, 10mM, 8.5mM)
- ADDRESSES neonatal metabolic consequences of early maternal hyperglycaemia not addressed by late treatment
- Follow up study needed-mother and offspring

For the 30-70% of women with early GDM, 24-28 weeks is too late-Yes! We should diagnose and treat!

Thanks to

Women participating and their families

TOBOGM project managers and research staff at each site

NHMRC (grants 1104231 and 2009326)

Region Örebro Research Committee, Sweden, Dnr OLL-970566, OLL-942177;

Medical Scientific Fund of the Mayor of Vienna, project 15205

South Western Sydney Local Health District Academic Unit Fund

Western Sydney University (Ainsworth Trust)

Central Team: Claudia Bishop, Lisa Vizza, Jodie Nema, Jincy Immanuel



TOBOGM Study

TOBOGM Consortium

Coordinating Principal Investigator:

Professor David Simmons

Co Investigators:

Professor William Hague

Professor Helena Teede

Professor Ngai Wah Cheung

Associate Professor Emily Hibbert

Professor Christopher Nolan

Professor Michael Peek

Associate Professor Vincent Wong

Associate Professor Jeff Flack

Professor Mark McLean

Professor Alexandra Kautzky-Willer

Dr Jürgen Harreiter,

Dr Arianne Sweeting

Dr Emily Gianatti

Associate Professor Helena Backman

Professor Viswanathan Mohan

TOBOGM Consortium

Associate Investigators:

Raiyomand Dalal

Rohit Rajagopal

Suja Padmanabhan

Associate Professor Eric Shwarz

Professor Glynis Ross

Doctor Uma Ram

Doctor Suja Padmanabhan

Doctor Ranjit Mohan Anjana

Doctor Suzette Coat

Professor Doctor Herbert Kiss

Associate Professor Georgia Soldatos

Dr Victoria Rudland



TOBOGM Study

Thank you

